Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
1998-05-04
2002-12-10
Bui, Phuong T. (Department: 1638)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S204100, C424S278100, C424S001210, C435S007100, C435S069300, C435S070100, C435S235100, C435S243000, C435S320100, C435S325000, C514S04400A, C530S350000, C536S023720
Reexamination Certificate
active
06491921
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to an avian polyomavirus vaccine and to a method of preventing avian polyomavirus infection in
Psittaciformes.
2. Background Art
The first acute, generalized infection associated with avian polyomavirus was described in 1980 in young psittacine birds and was called budgerigar fledgling disease (Davis, R. R. et al., “A viral disease of fledgling budgerigars,”
Avian Dis.,
1981, 25:179-183; Bozeman, L. H., et al., “Characterization of a papovavirus isolated from fledgling budgerigars,”
Avian Dis.,
1981, 25:972-980; Bernier, G., et al., “A generalized inclusion body disease in the budgerigar (
Melopsittacus undulatus
) caused by a papovavirus-like agent,”
Avian Dis.,
1981, 25:1083-1092; Dykstra, M. J., et al., “Investigations of budgerigar fledgling disease virus,”
Am. J. Vet. Res.,
1984, 45:1883-1887; Lehn, H., Muller, H., “Cloning and characterization of budgerigar fledgling disease virus (BFDV), an avian polyomavirus,”
Virology,
1986, 151:362-370). Since its discovery in 1980, avian polyomavirus has been associated with disease in a number of different species of companion and aviary birds including Budgerigars, caiques, macaws, Amazon parrots, conures, cockatoos, lovebirds, Splendid Parakeet, Pionus Parrots, African Grey Parrots, Eclectus Parrots, Cockatiels, finches and lories (Davies et al., 1981; Bozeman et al., 1981; Bernier et al., 1981; Lehn and Muller, 1986; Jacobson, E. R., et al., “Epornitic of papova-like virus-associated disease in a psittacine nursery,”
J. Am. Vet. Med. Assoc.,
1984, 185:1337-1341; Clubb, S. L., Davis, R. B., “Outbreak of papova-like viral infection in a psittacine nursery-a retrospective view,”
Proc. Assoc. Avian Vet.,
Toronto, 1984, 121-129; Graham, D. L., “An update on selected pet bird virus infections,”
Proc. Assoc. Avian Vet
., Toronto, 1984, 267-280; Gaskin, J. M., “Psittacine viral disease: A perspective,”
J. Zoo. Wildl. Med.,
1989, 20:240-264; Johnston, K. M., Riddell, C., “Intranuclear inclusion bodies in finches,”
Can. Vet. J.,
1986, 27:432-434; Marshall, R., “Papova-like virus in a finch aviary,
Proc. Assoc. Avian Vet.,
1989, 203-207; Schmidt, R. E., et al., “Morphologic identification of papovavirus in a Moluccan cockatoo (
Cacatua moluceensis
) with neurologic signs,”
Assoc. Avian Vet. Today,
1987, 1:107-108; Pass, D. A., et al., “A papova-like virus infection of splendid parakeets (
Neophema splendida
),”
Avian Dis.,
1987, 31:680-684; Pass, D. A., “A papova-like virus infection of lovebirds (
Agapornis sp
.(,”
Aus. Vet. J.;
1985, 82:318-319).
The type of clinical disease in Budgerigars, for example, depends upon the age and condition of birds when exposure to the virus occurs. Neonates from infected flocks may develop normally for 10-15 days and then suddenly die with no premonitory signs. Other infected hatchlings may develop clinical signs that include abdominal distention, subcutaneous hemorrhage, tremors of the head and neck, ataxia and reduced formation of down and contour feathers feather abnormalities,”
J. Vet. Sci.
46:577-587, 1984; Bernier et al., 1984; Clubb and Davis, 1984; Schmidt et al., 1987; Histopathology Reports #SC90-0637 and #SC90-0638, Schubot Exotic Bird health Center, Texas A&M University; Vernot, J., personal communication; Dykstra, M. J., Bozeman, L. H., “A light and electron microscopic examination of budgerigar fledgling disease virus in tissue and in cell culture.
Avian Pathol.
11:11-18, 1982). Infections have also been associated with decreased hatchability and embryonic death (Hudson, L., Hay, F. C., “Isolation and structure of immunoglobulins,” Hudson, L., Hay, F. C. Ed.,
Practical Immunology
, Boston, 1980, 156-202). Mortality rates can be as high as 100% in affected hatchlings. Surviving birds often exhibit dystrophic primary tail feathers, lack of down feathers on the back and abdomen, and lock of filoplumes on the head and neck. Additionally, surviving birds with primary feather abnormalities are usually unable to fly.
In larger psittacine birds, polyomavirus infections may cause peracute death with no premonitory signs, or acute death after development of clinical changes including depression, anorexia, weight loss, delayed crop-emptying, regurgitation, diarrhea, dehydration, subcutaneous hemorrhages, dyspnea, polyuria, and posterior paresis and paralysis (Pass et al., 1987; Johnston and Riddell, 1986; Mathey, W. J., Cho, B. R., “Tremors of nestling budgerigars with budgerigar fledgling disease,”
Proc.
33
rd West Poult. Dis. Conf.,
1984, 102; Woods, L., “Papova-like virus in a purple finch,”
J. Zoo. Wildl. Med.,
1989, 218-218; Gaskin, J. M., “The serodiagnosis of psittacine viral infections,”
Assoc. Avian Vet
. Honolulu, 1988, 7-10). Characteristic lesions associated with a polyomavirus infection have been demonstrated in companion birds from the United States (Jacobson et al., 1984; Clubb and Davis, 1984; Graham, 1984), Canada (Gough, J. F., “Outbreaks of budgerigar fledgling disease in three aviaries in Ontario,:
Can. Vet. J.,
1989, 30:672-674, Bernier et al., 1984), Japan (Hirai et al., 1984), Italy (Pascucci, S., et al., “Malattia da virus papova-simile nel papagallino ondulato (
Melopsittacus undulatus
),
Clin. Med
. (
Milan
), 1983, 106:38-41), Hungary (Szotjkov, V., et al., “A hullamous papagaj (
Melopsittacus Undulatus
) papovavirus okozta megbetegedesenek hazai megallapitasa,
Magy Allatorv Lapja
1985, 40:50-63), Germany (Krautwald, M-E, Kaleta, E. F., “Relationship of French moult and early virus induced mortality in nestling budgerigars,”
Proc.
8
th Intl. Cong. World Vet. Poult. Assoc.,
1985, 115) and Australia (Pass et al., 1987; Pass, 1985).
Immunodiffusion and virus neutralization techniques have been used to demonstrate anti-polyomavirus antibodies in psittacine birds (Jacobson et al., 1984; Clubb and Davis, 1984; Gaskin, 1989; Davis et al., 1981; Gaskin, 1988; Lynch, J., et al., “Isolation and experimental chicken-embryo-inoculation studies with budgerigar papovavirus,”
Avian Dis.
1984, 28:1135-1139; Wainwright, P. O., et al., “Serological evaluation of some psittaciformes for budgerigar fledgling disease virus,”
Avian Dis.
1987, 31:673-676). During epornitics in mixed psittacine bird collection, infected survivors and asymptomatic birds exposed to them have been shown to develop anti-polyomavirus neutralizing antibodies (Jacobson et al., 1984; Clubb and Davis, 1984; Wainwright et al., 1987). Seronegative young adult birds will seroconvert when housed adjacent to seropositive breeding adults; indicating that an antibody response does occur following natural exposure to the virus (Jacobson et al., 1984; Clubb and Davis, 1984; Wainwright et al., 1987; Davis, R. B., “Budgerigar fledgling disease (BFD), 32
nd West Poult. Dis. Conf.,
1983, 104). However, prior to the present invention it had not been determined whether this antibody response could be induced through vaccination or whether the resulting immunologic response would be protective.
In the past, attempts at producing a vaccine against avian polyomavirus have been unsuccessful. The existence of subclinical infections and chronically infected carrier birds, coupled with a lack of understanding of the epidemiologic and pathophysiologic characteristics of infection have all contributed to the lack of success.
Consequently, avian polyomavirus infections continue to cause high levels of mortality in companion and aviary birds, resulting in pscyhological distress for clients and financial burdens for aviculturists and retail distributors despite discovery of the virus over 14 years ago. Therefore, there exists a long-felt need in the art for a safe and effective vaccine against avian polyomavirus which is cross-protective against the disease in multiple species of
Psittaciformes.
Another problem associated with vaccine failure in
Psittaciformes
has been the lack of a suitable adjuvant. Two killed oil-adjuvanted herpsevirus (Pacheco's disease virus) vaccines that were conditionally li
Burnley Victoria
Pesti Denise
Poet Steven
Ritchie Branson W.
Bui Phuong T.
Needle & Rosenberg P.C.
University of Georgia Research Foundation Inc.
LandOfFree
Avian polyomavirus vaccines in psittacine birds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Avian polyomavirus vaccines in psittacine birds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Avian polyomavirus vaccines in psittacine birds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2930735